文献速递其他结缔组织病

靶向幼年皮肌炎的干扰素反应:Siglec-1作为JAK抑制剂疗效的体外生物标志物

Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

研究建立以Siglec-1为读数、评估不同JAK抑制剂抑制干扰素介导反应的体外模型。健康供者外周血单个核细胞经I/II型干扰素、TLR激动剂及患者血浆/血清刺激后,Siglec-1在CD14+单核细胞上的诱导可被JAK抑制剂和IFNAR阻断抗体抑制;JDM血浆诱导的Siglec-1水平与临床疾病活动度和IFN-β血浆水平强相关。结论认为Siglec-1是简便可靠的I型干扰素反液体外标志物,JDM的I型干扰素特征可能主要由IFN-β驱动。

要点

  • Siglec-1经I型干扰素及TLR-3/7/9激动剂刺激18小时后诱导,IFN-γ诱导极小。
  • JAK抑制剂以剂量依赖方式抑制IFN-α和IFN-β诱导的Siglec-1,IFNAR阻断可预防I型干扰素及TLR介导的诱导。
  • JDM血浆诱导的Siglec-1水平与临床疾病活动度及IFN-β血浆水平强相关,JDM的I型干扰素特征可能主要由IFN-β驱动。

核心结论

  • Siglec-1是简便可靠的I型干扰素反液体外标志物,其诱导可被JAK抑制剂抑制。
  • JDM的I型干扰素特征可能主要由IFN-β驱动。
  • 该检测方法有望用于JDM及其他干扰素驱动疾病的精准治疗策略。

研究设计与样本

  • 体外研究:健康供者外周血单个核细胞与I型和II型干扰素、TLR激动剂及JDM、DM、JSLE、COVID-19患者和健康供者的血浆或血清共培养。
  • 用流式细胞术分析CD14+单核细胞上Siglec-1表达。
  • 抑制实验包括预孵育JAK抑制剂(非戈替尼、托法替布、巴瑞替尼、芦可替尼、氘可来昔替尼)和干扰素-α/β受体(IFNAR)阻断抗体。
  • 在JDM患者中分析血浆诱导的Siglec-1水平与临床疾病活动度的相关性,以及与IFN-α和IFN-β血浆水平的相关性。

主要发现

  • I型干扰素及TLR-3/7/9激动剂刺激18小时后诱导Siglec-1,IFN-γ诱导极小。
  • IFNAR阻断可预防I型干扰素及TLR介导的Siglec-1诱导。
  • JAK抑制剂以剂量依赖方式抑制IFN-α和IFN-β诱导的Siglec-1。
  • JDM、DM、JSLE、COVID-19患者血浆或血清与健康单核细胞共培养可诱导Siglec-1表达,该诱导可被JAK抑制剂和IFNAR阻断抑制。
  • JDM血浆诱导的Siglec-1水平与临床疾病活动度强相关,与IFN-β血浆水平强相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: For IFN-driven diseases, such as juvenile dermatomyositis (JDM), there is a critical need for targeted therapies. We aimed to develop an in vitro model, using Siglec-1 as read-out, to evaluate inhibition of IFN-mediated responses with different JAK inhibitors (JAKi). METHODS: Healthy donor (HD) PBMCs were cultured with type I and II IFNs, TLR agonists and plasma or serum from patients (JDM, DM, JSLE, COVID-19) and HDs. Siglec-1 expression on CD14+ monocytes was analyzed using flow cytometry. Inhibitory assays involved pre-incubation with JAKi (filgotinib, tofacitinib, baricitinib, ruxolitinib, deucravacitinib) and interferon-α/β receptor (IFNAR)-blocking antibody. Correlations between plasma-induced Siglec-1 levels and clinical disease activity were analyzed in JDM patients, as well as correlations with IFN-α and -β plasma levels. RESULTS: Siglec-1 was induced after 18 h of stimulation with type I IFNs and TLR-3/7/9 agonists, with minimal induction by IFN-γ. IFNAR blockade prevented type I IFN- and TLR-mediated induction. JAKi inhibited Siglec-1 induction by IFN-α and -β in a dose-dependent manner. Co-culture with plasma or serum from patients with IFN-driven diseases induced Siglec-1 expression on healthy monocytes, which could be inhibited by JAKi and IFNAR blockade. Siglec-1 levels induced by JDM plasma correlated strongly with clinical disease activity and IFN-β plasma levels. CONCLUSION: Siglec-1 is an easy and reliable in vitro marker for type I IFN responses. Its induction can be inhibited by JAKi. The type I IFN signature in JDM is likely predominantly driven by IFN-β. This assay holds promise for precision treatment strategies in JDM and other IFN-driven diseases.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Veldkamp SR, Reugebrink M, Evers SW, et al. Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy. Rheumatology (Oxford). 2025. PMID: 40372702. doi:10.1093/rheumatology/keaf227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。